Sanofi abandons eczema drug approval efforts in another blow to OX40 class
While amlitelimab elicited durable responses in AD, Sanofi does not believe the drug is meaningfully differentiated from current eczema treatment offerings.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Turning AI skeptics into AI advocates through high-integrity data
Keeping pace with generative AI in pharmaceutical and healthcare organisations
Pharma Meets AI Conference 2026: Key barriers to scaling AI in drug development
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design